PETQ - PetIQ, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
34.51
-0.52 (-1.48%)
At close: 4:00PM EDT

34.51 0.00 (0.00%)
After hours: 4:19PM EDT

Stock chart is not supported by your current browser
Previous Close35.03
Open34.85
Bid33.51 x 1000
Ask34.94 x 800
Day's Range32.31 - 35.20
52 Week Range17.03 - 37.45
Volume1,445,373
Avg. Volume531,790
Market Cap886.589M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.67
Trade prices are not sourced from all markets
  • Why Chipotle Mexican Grill, Tilray, and PetIQ Jumped Today
    Motley Fool2 days ago

    Why Chipotle Mexican Grill, Tilray, and PetIQ Jumped Today

    Find out which of these stocks had the biggest gains.

  • Why PetIQ, Inc. Is Soaring Today
    Motley Fool2 days ago

    Why PetIQ, Inc. Is Soaring Today

    Shares surged after the company reported second-quarter results that exceeded expectations.

  • MarketWatch2 days ago

    PetIQ shares soar 10% after quarterly sales nearly double

    MARKET PULSE PetIQ Inc. (petq) shares soared 10% in Wednesday premarket trading after the pet health and wellness company reported second-quarter sales that nearly doubled. PetIQ reported sales of $171.

  • Associated Press3 days ago

    PetIQ: 2Q Earnings Snapshot

    The Eagle, Idaho-based company said it had net income of 16 cents per share. Earnings, adjusted for non-recurring costs, came to 66 cents per share. The results topped Wall Street expectations. The average ...

  • GlobeNewswire3 days ago

    PetIQ, Inc. Reports Second Quarter 2018 Financial Results

    Second Quarter Net Sales Increase 96% Year-Over-Year to $171.1 Million. Opened 20 Wellness Centers Year-to-Date. Company Raises Net Sales Outlook for Full Year 2018.

  • ACCESSWIRE3 days ago

    PetIQ, Inc. Class A to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / PetIQ, Inc. Class A (NASDAQ: PETQ ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern Time. ...

  • GlobeNewswire24 days ago

    PetIQ, Inc. to Report Second Quarter 2018 Results on Tuesday, August 14th

    EAGLE, Idaho, July 24, 2018-- PetIQ, Inc., a leading pet medication and wellness company, today announced it will report results for the second quarter ended June 30, 2018 on Tuesday, August 14, 2018 after ...

  • ACCESSWIRE2 months ago

    Free Stock Performance Review on Zoetis and Three Additional Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on ZTS sign up now at www.wallstequities.com/registration. Under evaluation this morning are these four stocks: Flexion Therapeutics Inc. (NASDAQ: FLXN), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), PetIQ Inc. (NASDAQ: PETQ), and Zoetis Inc. (NYSE: ZTS).

  • GlobeNewswire2 months ago

    PetIQ, Inc. to Participate in the Jefferies 2018 Consumer Conference

    EAGLE, Idaho, June 06, 2018-- PetIQ, Inc., a leading pet medication and wellness company, today announced that management will participate in the Jefferies 2018 Consumer Conference in Nantucket, MA.. The ...

  • GlobeNewswire3 months ago

    PetIQ, Inc. to Participate in the 38th Annual William Blair Growth Stock Conference

    EAGLE, Idaho, May 31, 2018-- PetIQ, Inc., a leading pet medication and wellness company, today announced that management will participate in the 38 th Annual William Blair Growth Stock Conference in Chicago, ...

  • ACCESSWIRE3 months ago

    Blog Exposure - Karyopharm Inked Deal with Antengene for Development and Commercialization of Selinexor, Eltanexor, Verdinexor, and KPT-9274 in Asia

    LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Karyopharm Therapeutics Inc. (NASDAQ: KPTI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KPTI as the Company's latest news hit the wire. On May 24, 2018, the Company announced that it has signed an exclusive license agreement with Antengene Corp. for the development and commercialization of four of Karyopharm's novel, oral drug candidates, including selinexor, eltanexor, verdinexor, and KPT-9274. Active-Investors.com is currently working on the research report for PetIQ, Inc. (NASDAQ: PETQ), which also belongs to the Healthcare sector as the Company Karyopharm Therapeutics.

  • PetIQ, Inc. (PETQ) Q1 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    PetIQ, Inc. (PETQ) Q1 2018 Earnings Conference Call Transcript

    PETQ earnings call for the period ending March 31, 2018.

  • Associated Press3 months ago

    PetIQ: 1Q Earnings Snapshot

    The Eagle, Idaho-based company said it had a loss of 14 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 9 cents per share. The results beat Wall Street expectations. ...

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Advanced Micro Devices, Inc. (NASDAQ: AMD ) stock ...

  • Benzinga5 months ago

    8 Stocks Moving In Tuesday's After-Hours Session

    Gainers RF Industries Ltd. (NASDAQ: RFIL ) shares are up 31 percent following a first quarter sales beat. Earnings came in at 5 cents per share in the quarter up from a loss of 2 cents in the same quarter ...

  • Associated Press5 months ago

    PetIQ reports 4Q loss

    On a per-share basis, the Eagle, Idaho-based company said it had a loss of 25 cents. Earnings, adjusted for pretax expenses and costs related to mergers and acquisitions, were 21 cents per share. The results ...